44th week of 2013 patent applcation highlights part 44 |
Patent application number | Title | Published |
20130287791 | MODULATION OF HISTONE H2B MONOUBIQUITINATION AND TREATMENT OF CANCER - Provided are methods and compositions for treatment of cancer. In particular, these methods and compositions may include an inhibitor of a deubiquitinating enzyme. In certain aspects, these methods and compositions may include a modulator of glucose metabolism. Also provided are methods of assaying the glucose content of cells and tissues using detection of uH2B. | 2013-10-31 |
20130287792 | COMPOSITIONS AND METHODS TO BLOCK MTB-MEDIATED EVASION - Method and compositions are disclosed for inhibiting Mtb-mediated evasion of host immunity or treating a disease or condition caused by Mtb infection in subject or patient, administering an effective amount of a molecular inhibitor, an isolated Mtb EIS peptide, polynucleotide encoding an Mtb EIS peptide, an EIS polynucleotide, or biological equivalents of each thereto. | 2013-10-31 |
20130287793 | QSOX1 as an Anti-Neoplastic Drug Target - The present invention provides methods for tumor treatment by administering an inhibitor of quiescin sulfhydryl oxidase 1 (QSOX1), compositions comprising such inhibitors, and methods for identifying such inhibitors. | 2013-10-31 |
20130287794 | METHODS FOR THE TREATMENT OR PREVENTION OF SYSTEMIC SCLEROSIS - The invention is in the field of molecular immunology, more in particular, in the field of the prevention or treatment of autoimmune diseases, more in particular, systemic sclerosis or scleroderma. The invention is based on the observation that SSC patients have an elevated plasma level of CXCL4. This was found to contribute to the pathogenesis of SSc, in particular, fibrosis. When CXCL4 was neutralized in in vitro experiments, the fibrotic effects could be neutralized. This led us to conclude that SSc may be cured by reducing the plasma level of CXCL4. The invention, therefore, relates to a method for treatment or prevention of fibrosis in patients with scleroderma, wherein the plasma level of CXCL4 is reduced. | 2013-10-31 |
20130287795 | ANTI-EPHRIN-B2 ANTIBODY AND USE THEREOF - The present invention relates to a novel antibody against ephrin B2 and its use to detect the protein and as a medicament for inhibiting angiogenesis and lymphangiogenesis in the treatment of diseases in which these processes are implicated, for example, cancer. | 2013-10-31 |
20130287796 | Sp35 Antibodies and Uses Thereof - Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-Sp35 antibody. | 2013-10-31 |
20130287797 | COMBINATION OF CD37 ANTIBODIES WITH BENDAMUSTINE - The present invention relates to immunotherapies that are based on depletion of CD37-positive cells such as B-cells. The present invention provides methods for reduction of CD37-positive cells such as B-cells in an individual/patient using a combination of CD37 antibody/antibodies and bendamustine. The combination of CD37 antibodies and bendamustine is shown to have a synergistic effect. The application further provides materials and methods for treatment of diseases involving aberrant B-cell activity. | 2013-10-31 |
20130287798 | USES OF MONOCLONIAL ANTIBODY 8H9 - This invention provides an antibody that binds the same antigen as that of monoclonal antibody 8H9, wherein the heavy chain CDR (Complementary Determining Region)1 comprises NYDIN, heavy chain CDR2 comprises WIFPGDGSTQY, heavy chain CDR3 comprises QTTATWFAY, and the light chain CDR1 comprises RASQSISDYLH, light chain CDR2 comprises YASQSIS, and light chain CDR3 comprises QNGHSFPLT. In another embodiment, there is provided a polypeptide that binds the same antigen as that of monoclonal antibody 8H9, wherein the polypeptide comprises NYDIN, WIFPGDGSTQY, QTTATWFAY, RASQSISDYLH, YASQSIS, and QNGHSFPLT. | 2013-10-31 |
20130287799 | ABETA CONFORMER SELECTIVE ANTI-ABETA GLOBULOMER MONOCLONAL ANTIBODIES - The subject invention relates to monoclonal antibodies that may be used in the treatment and diagnosis of Alzheimer's Disease. In particular, the present invention relates to monoclonal antibodies referred to as 10F4 and 3C5 and to other monoclonal antibodies (e.g., murine, human or humanized) having similar properties thereto. | 2013-10-31 |
20130287800 | IMMUNIZATION WITH AMYLOID-BETA OLIGOMERS - The present invention provides methods of immunization against Alzheimer's Disease and compositions for use in such methods. | 2013-10-31 |
20130287801 | BIOMARKERS, USES OF BIOMARKERS AND A METHOD OF IDENTIFYING BIOMARKERS - The invention relates to the use of one or more of protein myoferlin, protein latent-transforming growth factor beta binding protein 2, protein transforming growth factor beta induced protein ig-h3, protein adipocyte enhancer-binding protein 1, protein EMILIN1, protein periostin, protein CD97, protein prolargin, protein Thy-1 membrane glycoprotein, protein growth hormone inducible transmembrane protein, protein biglycan, protein EPCAM and protein EMILIN2 as a biomarker for colorectal carcinoma (CRC) liver metastasis, or a predisposition thereto. The invention also relates to ligands directed to the above-mentioned biomarkers, for use in the therapeutic and/or prophylactic treatment of CRC liver metastasis. | 2013-10-31 |
20130287802 | TARGETED/IMMUNOMODULATORY FUSION PROTEINS AND METHODS FOR MAKING SAME - The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells. | 2013-10-31 |
20130287803 | NOVEL USES OF VEGFXXXB - The invention provides VEGF | 2013-10-31 |
20130287804 | IMMUNOGENIC POLYPEPTIDES HAVING AN IMMUNOGENIC SCAFFOLD PROTEIN AND A LOOP PEPTIDE, PRESENTING A 3074- OR 2219/2557- MONOCLONAL ANTIBODY-TARGETED EPITOPE, WHICH IS PRESENT IN THE HIV GP120 PROTEIN - The present invention is directed to a recombinant immunogenic polypeptide. The polypeptide includes a loop peptide inserted into an immunogenic scaffold protein. The loop polypeptide has an amino acid sequence which presents the 3074 mAb- or the 2219/2557 mAb-targeted epitope of the HIV gp120 protein and not other known epitopes of the HIV gp120 protein. When used as an immunogen, the polypeptide induces an antibody response which neutralizes heterologous HIV-1 viruses in a pattern similar to that observed for the 3074 mAb- or the 2219/2557 mAb-targeted epitope, respectively. Pharmaceutical compositions containing the immunogenic polypeptide as well as methods of making and using it are also disclosed. | 2013-10-31 |
20130287805 | C18ORF54 PEPTIDES AND VACCINES INCLUDING THE SAME - Peptide vaccines against cancer are described herein. In particular, isolated epitope peptides or immunogenic fragments derived from SEQ ID NO: 35, that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) are provided. The amino acid sequences of the peptide of interest may be optionally modified with the substitution, deletion, insertion, or addition of one, two, or several amino acids sequences. Pharmaceutical compositions and methods of treating cancer that include such peptides are also provided. | 2013-10-31 |
20130287806 | IMMUNE-MODULATING AGENTS AND USES THEREFOR - This invention discloses the use of Heminth Defense Molecules in methods and compositions for modulating immune responses including treating or preventing undesirable or deleterious immune responses. | 2013-10-31 |
20130287807 | COMPOUNDS FOR TREATING SYMPTOMS ASSOCIATED WITH PARKINSON'S DISEASE - The present invention relates to a compound comprising a peptide for treating, preventing and/or ameliorating motor symptoms of Parkinson's disease, said peptide having a binding capacity to an antibody which is specific for an epitope of the amyloid-beta-peptide (Aβ). | 2013-10-31 |
20130287808 | VACCINES FOR PREVENTING MENINGOCOCCAL INFECTIONS - The present invention stems from the finding that the interaction between the β2 adrenoceptor (β2AP) and type IV pilus-associated proteins initiates a process leading to the opening of the blood-brain barrier. The invention therefore pertains to a vaccine for preventing the spreading of meningococci into the meningeal space, wherein said vaccine allows the production of antibodies inhibiting the interaction between the type IV pilus-associated proteins and the β2AP. | 2013-10-31 |
20130287809 | MYCOBACTERIUM ANTIGENIC COMPOSITION - Immunogenic compositions comprising an Rv1196 related antigen, wherein the conductivity of the composition is 13 mS/cm or lower, or the concentration of salts of the composition is 130 mM or lower, and their use in medicine, are provided. | 2013-10-31 |
20130287810 | VACCINE COMPOSITIONS AND USES THEREOF - The present invention relates to vaccine compositions and uses thereof. Embodiments of the present invention provide oral bacterial (e.g., probiotic lactic acid bacteria) vaccine delivery systems comprising an antigen and a dendritic cell-targeting peptide. Such compositions target vaccines to dendritic cells, resulting in a high level of humoral and acquired immunity, including both mucosal and systemic immunity. Such delivery systems find use in the specific delivery of a wide variety of oral vaccines to subjects. | 2013-10-31 |
20130287811 | Method for Producing Viral Vaccines - The present invention provides a method for the manufacture of a preparation comprising virus antigens comprising
| 2013-10-31 |
20130287812 | anti-HPV drug and its application in preparing medicines for treatment of HPV (human papilloma virus) infection - This invention disclosed an anti-HPV drug and its applications in preparing medicines for treatment of HPV (human papilloma virus) infection. This drug was characterized by using human rabies vaccine as its active ingredient and being produced by adding pharmacologically acceptable carriers. This invention also disclosed drug applications in preparing medicines for treatment of HPV infection, i.e. new applications of human rabies vaccines for preparing medicines against HPV infection. The anti-HPV drug described in this invention (i.e. human rabies vaccine) had obvious treatment effects on HPV infection. According to the animal tests and preclinical observation, this drug provided satisfactory and beneficial effects and had the characteristics of safety, effectiveness and nearly no recurrence after treatment; the negative-conversion rate in patients with positive HPV-infection reached 90% after treatment. | 2013-10-31 |
20130287813 | Polypeptides and Immunizing Compositions Containing Gram Positive Polypeptides and Methods of Use - The present invention provides isolated polypeptides isolatable from a | 2013-10-31 |
20130287814 | DNA Expression Construct - The invention relates to a minimalistic gene expression construct, its transfer into cells and its use for gene expression for molecular-medical applications. According to the disclosure, a DNA construct for gene expression is provided, wherein the construct is a linear and open-chained DNA double strand comprising a promoter sequence, a coding sequence and a termination signal, wherein the construct comprises at least one L-DNA nucleotide. | 2013-10-31 |
20130287815 | METHODS FOR IN VITRO DIFFERENTIATION OF TH-17+ CELLS - The present invention is directed to an in vitro method for promoting differentiation and proliferation of human T helper lymphocytes that express IL17 (Th-IL17+ cells). The instant method may be used to generate a population of human T helper lymphocytes that express IL17 (Th-IL17+ cells) in vitro. Methods for screening to identify agents capable of modulating Th-IL17+ cell differentiation are also encompassed by the present invention. Isolated, pure populations of homogeneous Th-IL17+ cells that do not express cellular markers characteristic of Th1, Th2, or Treg cells are also encompassed herein. | 2013-10-31 |
20130287816 | P97 PROTEIN AND USES THEREOF AS VACCINE ADJUVANT - Immunogenic compositions comprising a p97 adhesin adjuvant polypeptide, or a nucleic acid encoding said p97 adhesin adjuvant polypeptide, and a heterologous antigen are disclosed. Uses of the p97 adhesin adjuvant polypeptide or nucleic acid, or immunogenic compositions comprising same, for inducing an immune response against a heterologous antigen in a subject are also disclosed. | 2013-10-31 |
20130287817 | FLOWABLE IMPLANT WITH CROSSLINKABLE SURFACE MEMBRANE - A flowable biomedical implant for application to a bone defect to promote bone growth is provided. The flowable biomedical implant comprises a carrier matrix including a biodegradable polysaccharide and ceramic material. An impermeable membrane can be integrally formed at the surface of the carrier matrix by applying a crosslinking agent to the biodegradable polysaccharide mixed with ceramic materials. | 2013-10-31 |
20130287818 | NON-AQUEOUS COMPOSITIONS AND METHODS FOR BONE HEMOSTASIS - Bone hemostat compositions, and methods for their use and manufacture are provided. Exemplary hemostatic compositions include polymeric components such as random and non-random copolymers, natural polymers, ceramics, reactive group polymers, and combinations thereof. Bone compositions may be used during surgical procedures, and may be applied to bone to inhibit or prevent bleeding from bone. | 2013-10-31 |
20130287819 | BIOADHESIVE POLYMER-BASED CONTROLLED-RELEASE SYSTEMS, PRODUCTION PROCESS AND CLINICAL USES THEREOF - The invention relates to release systems based on bioadhesive polymers, their manufacturing process and to their uses in the medical, pharmaceutical, cosmetic, cosmeceutical and nutraceutical fields. In particular, these release systems are provided for local application onto skin and mucosal lesions, in particular for the treatment of pathologies of the buccal mucosa. | 2013-10-31 |
20130287820 | ORAL DELIVERY VEHICLE AND MATERIAL - Compositions for an oral delivery vehicle are described as well as methods for their manufacture and administration. The oral delivery vehicles can be made in any size or shape and can further comprise a medicament or other substance or object to be orally delivered. The vehicle can, for example, take the form of a pouch or capsule. Alternatively, a medicament or other substance to be orally delivered can be coated with the composition. In another alternative, the medicament or other substance to be orally delivered can be dispersed within a matrix of the composition. The compositions for the oral delivery vehicle are also suitable for use as an animal food or treat or use as a hunting bait or lure. | 2013-10-31 |
20130287822 | De Novo Anembryonic Trophoblast Vesicles and Methods of Making and Using Them - Anembryonic, de novo, trophoblast vesicles are further characterized by (a) having the functional capacity for implantation, (b) being composed of a substantially perfect sphere having a hollow, acellular center, (c) having a cellular rim containing viable cells that are proliferating, and (d) having numerous tight-junctions among the viable cells in the rim. Embryos can be made by seeding trophoblast cells in a non-adherent cell aggregation device; incubating the cells in the device until the cells form functional anembryonic de novo trophoblast vesicles; and injecting an inner cell mass or embryonic stem cells into the functional anembryonic de novo trophoblast vesicles to thereby make the embryos. | 2013-10-31 |
20130287823 | PATCH - Disclosed is a patch excellent in storage stability and transdermal absorbability of midodrine and having good adhesion. The patch includes a backing and a medicated layer stacked on one surface of the backing so as to be integrated with the backing. The medicated layer contains 3 to 40% by weight of midodrine and 60 to 97% by weight of an acrylic adhesive including a copolymer formed by copolymerization of monomers including 60 to 98% by weight of an alkyl acrylate having an alkyl group with 1 to 12 carbon atoms and 2 to 40% by weight of 1-vinyl-2-pyrrolidone. In the medicated layer, part of midodrine is present in an undissolved state. | 2013-10-31 |
20130287824 | OIL-BASED MAKEUP COSMETIC PREPARATION - An oil-based makeup cosmetic preparation having an excellent feeling in use and a long wearability is provided. The cosmetic preparation comprises the following components each in the following amount relative to the entire cosmetic preparation:
| 2013-10-31 |
20130287825 | PHARMACEUTICAL COMPOSITIONS COMPRISING NANO SIZE DROPLETS OF SKIN WHITENING AGENTS - The present invention relates to pharmaceutical compositions comprising mono size droplets of skin whitening agents or salts thereof. In particular, the present invention relates to a stable pharmaceutical composition comprising skin whitening agents or salts thereof along with other pharmaceutically acceptable excipients which possess substantially improved skin whitening effects and also exhibits greater skin permeability. The invention also relates to processes for the preparation of such compositions. | 2013-10-31 |
20130287826 | COMPOSITE PARTICLES AND COMPOSITIONS WITH COMPOSITE PARTICLES - Composite particles and compositions with the composite particles are described. The particles have a polymeric base with or without voids and subparticles whereby the subparticles have indexes of refraction above and below the index of refraction of the polymeric base. When typically applied, the compositions impart excellent soft focus results on the skin of consumers. | 2013-10-31 |
20130287827 | COMPOSITION CONTAINING POLYUNSATURATED FATTY ACID - An object of the present invention is to provide a composition for external use comprising a polyunsaturated fatty acid having higher stability over time. The present invention provides the following composition, in which the stability over time of a polyunsaturated fatty acid is high. | 2013-10-31 |
20130287828 | COSMETIC COMPOSITION COMPRISING SILICA AEROGELS PARTICLES AND HYDROCARBON-BASED OILS - The present invention relates to a composition comprising a mixture of: hydrophobic silica aerogel particles with a N specific surface area per unit of mass (S | 2013-10-31 |
20130287829 | Controlling insects and arthropods using preconidial mycelium and extracts of preconidial mycelium from entomopathogenic fungi - The present invention utilizes the pre-sporulation (preconidial) mycelial stage of entomopathogenic fungi and extracts of the preconidial mycelium as insect and arthropod attractants and/or pathogens. The preconidial preparations can be employed to limit the zoonotic and plant diseases they transmit. The fungus can be cultivated on grain, wood, agricultural wastes or other cellulosic material and extracts can be made thereof. More than one fungus and substrate can be used in combination with one or more antimicrobial, antiprotozoal, antiviral, or genetically modified agents that result in reduced spread of contagions and lessens the damage they inflict on animals and plants. | 2013-10-31 |
20130287830 | PESTICIDE COMPOSITION DELIVERY VEHICLES - Vehicles for delivery and release of pesticide compositions are provided. In one aspect, the delivery vehicle is a capsule configured to resist release of a pesticide composition before application of the capsule at a locus where pest control is desired. The capsule is further configured to degrade following application at the locus where pest control is desired to facilitate release of the pesticide composition. In one particular but non-limiting form, the capsule includes a shell wall including a relatively high Bloom strength gelatin material and a plasticizer material, and the pesticide composition includes a fumigant such as 1,3-dichloropropene. Further embodiments, forms, objects, features, advantages, aspects, and benefits shall become apparent from the description and drawings. | 2013-10-31 |
20130287831 | Compositions And Methods For Preventing Or Reducing Resistance Of Insects To Insecticides - A method for preventing or reducing resistance to a pesticide of a substrate pest, which method comprises the administration to the substrate or the pest of a composition comprising: (a) a rapid-release formulation of an inhibitor of a factor causing or contributing to the resistance of the pest to the pesticide; and, substantially simultaneously, (b) a non-rapid release formulation of the pesticide. The invention also provides compositions suitable for use in such a method. | 2013-10-31 |
20130287832 | SOLUBLE NEEDLE ARRAYS FOR DELIVERY OF INFLUENZA VACCINES - Influenza vaccines are administered using solid biodegradable microneedles. The microneedles are fabricated from the influenza vaccine in combination with solid excipient(s) and, after penetrating the skin, they dissolve in situ and release the vaccine to the immune system. The influenza vaccine is (i) a purified influenza virus surface antigen vaccine, rather than a live vaccine or a whole-virus or split inactivated vaccine (ii) an influenza vaccine prepared from viruses grown in cell culture, not eggs, (iii) a monovalent influenza vaccine e.g. for immunizing against a pandemic strain, (iv) a bivalent vaccine, (v) a tetravalent or >4-valent vaccine, (vi) a mercury-free vaccine, or (vii) a gelatin-free vaccine. | 2013-10-31 |
20130287833 | Nitric Oxide Generating Medical Devices - Medical devices having a catalyst capable of catalyzing the generation of nitric oxide in vivo and methods of treating a vascular condition using the devices are provided. | 2013-10-31 |
20130287834 | ANTI-ADHERENT FORMULATION INCLUDING A CATIONIC OR NONIONIC ACRYLATE CO-POLYMER - Liquid formulations having anti-adherent properties are disclosed herein. The liquid anti-adherent formulation described herein acts to prevent the adherence of menses and/or fecal material to the skin in the labial and perianal regions during and after menstruation or defecation, respectively. The liquid anti-adherent formulation contains a carrier, a polymer selected from a nonionic acrylate co-polymer, cationic acrylate co-polymer, and combinations thereof. Anti-adherent formulation is found to be effective if a menses leave-on percentage as defined within the Menses Leave-On Percentage Test method described herein was less than 6.2% after two insults. | 2013-10-31 |
20130287835 | METHODS FOR STEPWISE DEPOSITION OF SILK FIBROIN COATINGS - The invention provides a method for the controlled assembly of layered silk fibroin coatings using aqueous silk fibroin material. The methods described herein can be used to coat substrates of any material, shape, or size. Importantly, the described methods enable control of the biomaterial surface chemistry, thickness, morphology and structure using layered thin film coatings, or bulk coatings. Furthermore, the methods can be performed in all water and do not require intensive chemical processing enabling controlled entrapment of labile molecules such as, drugs, cytokines, and even cells or viruses to generate functional coatings that can be used in a variety of applications. | 2013-10-31 |
20130287836 | HIGH STRENGTH CHITIN COMPOSITE MATERIAL AND METHOD OF MAKING - The present invention is directed to a composite laminar material with high mechanical strength and methods of fabricating the material. The invention also provides a method of attaching a medical implant device to tissue. | 2013-10-31 |
20130287837 | SOLID DRESSING FOR TREATING WOUNDED TISSUE - Disclosed are solid dressings for treated wounded tissue in mammalian patients, such as a human, comprising a haemostatic layer consisting essentially of a fibrinogen component and a fibrinogen activator, wherein the haemostatic layer(s) is cast or formed from a single aqueous solution containing the fibrinogen component and the fibrinogen activator. Also disclosed are methods for treating wounded tissue using these dressings and frozen compositions useful for preparing the haemostatic layer(s) of these dressings. | 2013-10-31 |
20130287838 | VACCINE ENGINEERING - The method and constructs disclosed and claimed herein allow to control peptide conformation by modulation of the peptide lipidation pattern, spacer and liposome composition, or via co-administration with small molecules. Accordingly, this technology can be applied to the rational design of liposomal vaccines and for the generation of safer and more efficacious therapies for a range of human disease, in particular those based on misfolded proteins. | 2013-10-31 |
20130287839 | USE OF THE CATHELICIDIN LL-37 AND DERIVATIVES THEREOF FOR WOUND HEALING - Use of the antimicrobial cathelicidin peptide II-37, N-terminal fragments of LL-37 or extended sequences of LL-37 having 1-3 amino acids in the C-terminal end, for stimulating proliferation of epithelial and stromal cells and thereby healing of wounds, such as chronic ulcers. The cytotoxic effect of LL-37 may be reduced by including a bilayer-forming polar lipid, especially a digalactosyldiacylglycerol, in pharmaceutical compositions and growth media comprising LL-37. | 2013-10-31 |
20130287840 | Bulk Enteric Capsule Shells - The present disclosure relates to aqueous compositions for use in the manufacture of capsule shells endowed with bulk enteric properties. The present disclosure also relates, in part, to aqueous dispersions suitable for the implementation of said manufacturing process, and to enteric capsule shells and hard capsules obtained therewith. | 2013-10-31 |
20130287841 | Drug with Activity against the Herpes Virus Family - The invention relates to medicine, and specifically to synthetic biologically active derivatives of carbopentoxysulfanilic acid. The novel substance comprises a (2,6-dichlorophenyl)amide salt of carbopentoxysulfanilic acid of general formula: | 2013-10-31 |
20130287842 | Hard Capsules - Publicly available pullulan hard capsule shells present certain drawbacks, notably a non fully satisfactory shell mechanical strength (i.e. shell brittleness) at shell low LOD. Improving this property is a particularly desirable goal for pullulan hard capsule shells. The present invention solves this and other objects by providing new hard pullulan capsule shells and capsules comprising (I) moisture, (II) a mono-, di-, and oligosaccharides free pullulan and (III) a setting system. Also provided are an aqueous composition and a dip-molding manufacturing method for the manufacture of such shells and capsules. | 2013-10-31 |
20130287844 | Agrochemical Formulation Comprising Encapsulated Pesticide - The present invention relates to microcapsules comprising a polyurea shell and a core, which contains a pesticide, a water-immiscible solvent A and at least 5 wt % of an aprotic, polar solvent B, which has a solubility in water from 0.5 to 20 g/l at 20° C., based on the total weight of the solvents in the core. It further relates to microcapsules comprising a shell and a core, which contains a pesticide and 2-heptanone; to a method for preparing said mircocapsules; to an aqueous composition comprising said microcapsules; and to a method for controlling phytopathogenic fungi and/or undesired plant growth and/or undesired attack by insects or mites and/or for regulating the growth of plants, with said mircocapsules. | 2013-10-31 |
20130287845 | Oral Drug Delivery System - Dosage forms and drug delivery devices suitable for administration of pharmaceutical compounds and compositions, including the oral drug administration of compounds. | 2013-10-31 |
20130287846 | ABUSE-PROOFED ORAL DOSAGE FORM - The present invention relates to an abuse-proofed oral dosage form with controlled release of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol for once daily administration, which comprises the active ingredient and/or one or more of the pharmaceutically acceptable salts thereof (A), at least one synthetic or natural polymer (C), delayed-release auxiliary substances, optionally physiologically acceptable auxiliary substances (B) and optionally a wax (D), component (C) or (D) in each case exhibiting a breaking strength of at least 500 N, preferably of at least 1000 N. | 2013-10-31 |
20130287847 | Solid Molecular Dispersion - The present invention relates to a solid molecular dispersion of fesoterodine hydrogen fumarate and a polymeric binder. The invention also relates to an inert core bead or particle which is coated with said solid molecular dispersion and to pharmaceutical formulations comprising such coated beads or particles. | 2013-10-31 |
20130287848 | Bromocriptine Formulations - The present application describes pharmaceutical formulations of bromocriptine mesylate and methods of manufacturing and using such formulations. The formulations are useful for improving glycemic control in the treatment of type 2 diabetes. | 2013-10-31 |
20130287849 | FORMULATIONS AND METHODS FOR THE CONTROLLED RELEASE OF ACTIVE DRUG SUBSTANCES - Controlled release formulations and methods for preparing controlled release formulations for delivery of active drug substances are described herein. The formulations described herein may be employed to produce pharmaceutical compositions, such as controlled release dosage forms, adjusted to a specific administration scheme. | 2013-10-31 |
20130287850 | FORMULATIONS AND METHODS FOR THE CONTROLLED RELEASE OF ACTIVE DRUG SUBSTANCES - Controlled release formulations and methods for preparing controlled release formulations for delivery of active drug substances are described herein. The formulations described herein may be employed to produce pharmaceutical compositions, such as controlled release dosage forms, adjusted to a specific administration scheme. | 2013-10-31 |
20130287851 | LIQUID GANAXOLONE FORMULATIONS AND METHODS FOR THE MAKING AND USE THEREOF - In certain embodiments, the invention is directed to composition comprising stable particles comprising ganaxolone, wherein the volume weighted median diameter (D50) of the particles is from about 50 nm to about 500 nm. | 2013-10-31 |
20130287852 | COMPOSITIONS FOR NASAL ADMINISTRATION OF PHARMACEUTICALS - Compositions for nasal administration, which comprise a pharmaceutical, a physiologically active peptide, or a peptide-related compound, and as the carrier thereof, crystalline cellulose with a specific particle diameter and/or partially pregelatinized starch are provided. Such compositions improve the in vivo absorption efficiency of pharmaceuticals. | 2013-10-31 |
20130287853 | COMPOSITIONS AND METHODS FOR NANOPOLYMER-BASED NUCLEIC ACID DELIVERY - Provided herein are p-GlcNAc nanoparticle/nucleic acid compositions. In one aspect, the p-GlcNAc nanoparticle/nucleic acid compositions comprise deacetylated poly-N-acetylglucosamine lactate derivative nanoparticles less than 500 nm and a nucleic acid. Also, provided herein are methods for administering a nucleic acid to a subject, the method comprising administering to the subject a p-GlcNAc nanoparticle/nucleic acid composition. In certain embodiments, the p-GlcNAc nanoparticle/nucleic acid composition is administered subcutaneously to the subject. | 2013-10-31 |
20130287854 | COMPOSITIONS AND USES - According to the invention there is provided a method of treating and/or preventing the symptoms of Parkinson's disease comprising delivering apomorphine, optionally in combination with levodopa and/or a dopamine agonist that is not apomorphine, wherein apomorphine is administered by inhalation. | 2013-10-31 |
20130287855 | COMPOSITIONS BASED ON CLAY AND BEE POLLEN, METHOD FOR PREPARING SAME, AND NUTRITIONAL AND THERAPEUTIC USES THEREOF - The present invention relates to complexes of beepollen and clay, as well as to their preparation methods and to their therapeutic uses or as a food supplement, a functional food, in human and animal healthcare. | 2013-10-31 |
20130287856 | Drug Delivery Dispersion And Film Formed Therefrom - An active agent delivery dispersion includes water, 1 to 98 weight percent of a plurality of encapsulated particles dispersed in the water, and 0.1 to 20 weight percent of an active agent, each based on a total weight of the dispersion. The active agent is dispersed in the water independently from the plurality of encapsulated particles. Each of the particles includes a core and a layer including a silica disposed about the core. The plurality includes first and second populations of encapsulated particles. The core of the first population includes a first organopolysiloxane having at least two silicon-bonded alkenyl groups per molecule and a hydro-silylation catalyst. The core of the second population includes an organohydrogensiloxane having an average of greater than two silicon bonded hydrogen atoms per molecule and a second organopolysiloxane having at least two silicon-bonded alkenyl groups per molecule. | 2013-10-31 |
20130287857 | Vaccine Nanotechnology - The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides vaccine nanocarriers capable of stimulating an immune response in T cells and/or B cells, in some embodiments, comprising at least one immunomodulatory agent, and optionally comprising at last one targeting moiety and optionally at least one immunostimulatory agent. The invention provides pharmaceutical compositions comprising inventive vaccine nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive vaccine nanocarriers and pharmaceutical compositions thereof. The invention provides methods of prophylaxis and/or treatment of diseases, disorders, and conditions comprising administering at least one inventive vaccine nanocarrier to a subject in need thereof. | 2013-10-31 |
20130287858 | COMPOSITION AND METHOD TO IMPROVE BLOOD LIPID PROFILES AND OPTIONALLY REDUCE LOW DENSITY LIPOPROTEIN (LDL) PER-OXIDATION IN HUMANS - A composition and method which improves blood lipid profiles and optionally reduces low density lipoprotein (LDL) per-oxidation in humans by administering a therapeutic amount of a composition comprising krill oil in combination with astaxanthin or a mixture of fish oil derived, choline based, phospholipid bound omega-3 fatty acid mixture including phospholipid bound polyunsaturated EPA and DHA. In one embodiment, the krill oil is derived from | 2013-10-31 |
20130287859 | METHOD FOR TREATING PRUPRITUS WITH CARTILAGE EXTRACT - Disclosed herein is a method of treating psoriatic pruritus by topical administration of a cartilage extract to the affected areas of a patient's skin and a topical composition for use in practicing the method. | 2013-10-31 |
20130287860 | ANTIMICROBIAL AGENTS AND METHODS OF USE - The present application relates to novel antimicrobial compositions and methods of using said antimicrobial compositions for inhibiting and treating microbial growth, microbial infections, inflammatory diseases, viral diseases, cardiovascular diseases, diabetes and/or conditions that may be regulated or associated with microbial infections, such as cancer. | 2013-10-31 |
20130287861 | ANTIMICROBIAL AGENTS AND METHODS OF USE - The present application relates to novel antimicrobial compositions and methods of using said antimicrobial compositions for inhibiting and treating microbial growth, microbial infections, inflammatory diseases, viral diseases, cardiovascular diseases, diabetes and/or conditions that may be regulated or associated with microbial infections, such as cancer. | 2013-10-31 |
20130287862 | CLEANING, DISINFECTING AND MICROBICIDAL COMPOSITIONS - A microbicidal disinfecting composition and a method of preparing the same include the use of an acidifying agent that comprises at least one of an alkali metal bisulfate, ammonium bisulfate, or a combination thereof. The composition has broad-spectrum microbicidal properties and does not demonstrate cloudiness or precipitation when prepared, diluted, or otherwise exposed to hard water. | 2013-10-31 |
20130287863 | ISOTHIAZOLINONE BIOCIDES ENHANCED BY ZINC IONS - The present invention relates to an antimicrobial composition comprising an isothiazolinone, such as 1,2-benzisothiazolin-3-one, and a zinc compound selected from zinc salts, zinc oxides, zinc hydroxides or combinations thereof. Useful zinc salts include for example, oxides, sulfates, chlorides, and combinations thereof. In use, the zinc from the zinc compound enhances the antimicrobial activity to the isothiazolin-containing composition. This enhancement permits achieving the desired antimicrobial activity at a lower usage rate than is achieved using the isothiazolinone in the absence of the zinc compound. The antimicrobial composition can also contain co-biocides, such as pyrithiones, including zinc pyrithione or copper pyrithione. | 2013-10-31 |
20130287864 | METHOD FOR PRODUCING BIOACTIVE AGENT, BIOACTIVE AGENT PRODUCED THEREBY, COSMETIC, FRESHNESS-MAINTAINING AGENT, GROWTH PROMOTION AGENT, SOIL CONDITIONING AGENT, AND PHARMACEUTICAL STOCK SOLUTION - The object of the invention is to provide a bioactive agent in which the bioactive effectiveness of ferric iron salt and/or ferric ferrous iron salt contained therein is stabilized, making long term preservation possible, so that the bioactive agent can be useful as an original solution for medical use, as a soil conditioner, or the like. An iron-magnesium mixture solution is provided in the invention, wherein the iron-magnesium mixture solution is produced by mixing an aqueous solution containing a ferric iron salt and/or a ferric ferrous iron salt in a concentration of not less than 0.5 mol/L as iron in the ferric iron salt and/or the ferric ferrous iron salt, and an aqueous solution containing a magnesium salt in a concentration of not less than 0.2 mol/L as magnesium in the magnesium salt. | 2013-10-31 |
20130287865 | ANTIMICROBIAL SOLUTIONS AND METHODS - Antimicrobial solutions and delivery systems for them use liquid antimicrobial solutions with: at least 80% of total weight of a carrier liquid comprising water, alcohol or a mixture of water and alcohol; at least 0.0001% by weight of the solution of I | 2013-10-31 |
20130287866 | Nitric Oxide Amino Acid Esters for Improving Vascular Circulation, and Prophylaxis or Treatment of a Condition Associated with Impaired Blood Circulation - Use of nitric oxide amino acid esters for improving vascular circulation, and prophylaxis or treatment of a condition associated with impaired blood circulation, such as peripheral vascular disease. The nitric oxide amino acid esters may be co-administered with an antimicrobial in topical or transdermal compositions for improving vascular circulation, and prophylaxis or treatment of a condition associated with impaired blood circulation. | 2013-10-31 |
20130287867 | COMPOSITION USABLE IN THE TREATMENT OF CELLULAR DEGENERATION - The invention relates to a composition for use in the very rapid treatment of cell degeneration, in particular in oncologic field, characterized in that it is constituted by a compound of Potassium Bicarbonate and D-Ribose. | 2013-10-31 |
20130287868 | Pharmaceutical composition on the basis of Stachytarpheta sp., a process for obtaining the same and its use for treating vitiligo - This invention generally refers to the process to obtain a compound and a standard pharmaceutical product from one or more parts of plants of the | 2013-10-31 |
20130287869 | LIQUID ANIMAL REPELLANT CONTAINING OILS OF BLACK PEPPER AND CAPSICUM - The present invention provides a novel liquid animal repellant composition which is environmentally safe, non-toxic, long-lasting and efficacious against a wide variety of animals such as dogs, cats, raccoons, skunks, mice, rates, squirrels, chipmunks, deer, etc. | 2013-10-31 |
20130287870 | NOVEL USES FOR TRADITIONAL CHINESE MEDICINE - The present invention relates to the use of one or more Neuroaid2 components to activate K | 2013-10-31 |
20130287871 | REFRESHING BEVERAGE - The invention relates to a novel sweet-tasting refreshing beverage, which is free of phosphoric acid and instead contains at least 0.3% by weight/volume of gluconic acid, which is low in minerals, specifically contains less than 250 mg/liter of minerals, which is low in sugar, specifically contains at most 2.5% by weight/volume of sugar, wherein these sugars comprise at least 10% weight/weight galactose and in addition a proportion of isomaltulose and/or tagatose, and which has a glycemic index of at most 35 (GI<35). | 2013-10-31 |
20130287872 | COMPOSITION COMPRISING CINNAMON EXTRACT - The invention concerns a composition for lowering the glycemic index comprising, or consisting of an alcoholic extract of cinnamon in an amount of at least 10% by weight compared to the total weight of the composition, and optionally a carrier, a food composition comprising a composition for lowering the glycemic index in an amount ranging from 0.1% to 5% by weight compared to the total weight of the food composition, the use of a composition for lowering the glycemic index or of a food composition as a glycemic index lowering agent. | 2013-10-31 |
20130287873 | PHARMACEUTICAL COMPOSITION AND METHOD FOR PREPARING A MEDICATION FOR PROMOTING WOUND HEALING - The disclosure provides a pharmaceutical composition for promoting wound healing, including an effective amount of a | 2013-10-31 |
20130287874 | SPOONABLE YOGURT PREPARATIONS CONTAINING NON-REPLICATING PROBIOTIC MICRO-ORGANISMS - The present invention relates to the field of spoonable yogurt compositions. In particular, the present invention provides spoonable yogurt compositions comprising non-replicating probiotic micro-organisms. These non-replicating probiotic micro-organisms may be bioactive heat treated probiotic micro-organisms, for example. The present invention also relates to health benefits provided by these non-replicating probiotic micro-organisms. | 2013-10-31 |
20130287875 | FLUID FEEDER AND TIRE CURING DEVICE - A fluid feeder which is capable of removing foreign matter on the surface of a rotor is provided. The fluid feeder is provided with a rotor housing body on which a rotor housing chamber for housing a rotor of a canned electric motor is installed and a pump casing in which a fluid feeding chamber hermetically installed so as to be connected consecutively to the rotor housing chamber is installed and an impeller is housed inside the fluid feeding chamber. Further, a hollow pipe body is used to connect the vicinity of a side face of the fluid feeding chamber with an upper end of the rotor housing chamber. | 2013-10-31 |
20130287876 | PERFORATED PLATE - A perforated plate of a granulating device for thermoplastic plastic material, having nozzle openings, and wherein at least one side of the perforated plate has a functional layer in at least one region. The functional layer is thermally insulating as compared to the base material of the perforated plate, and is more abrasion-resistant than the base material of the perforated plate, and consists of an enamel coating. | 2013-10-31 |
20130287877 | RESIN TRANSFER MOLDING DEVICE AND RESIN TRANSFER MOLDING METHOD - A resin transfer molding (RTM) molding device is designed to mold a fiber-reinforced plastic (FRP) molded body by injecting a resin composition into a mold and by impregnating the molded body therewith. The resin composition is a chain curing polymer (CCP). A CCP accommodating layer is disposed adjacent to an outer side of the molded body. The layer contains the CCP. The layer is provided with a Vf limit value, the value defined by the curing characteristics of the CCP and the characteristics of dissipation of heat from the CCP to the exterior. An element for separating the molded body is disposed between the body and the layer. | 2013-10-31 |
20130287878 | Molding System having Material Preparation and Delivery Systems and Material-Mixing Assembly - A molding system ( | 2013-10-31 |
20130287879 | Quick-Change Molding System for Injection Molding - An injection molding system is disclosed that includes a mold insert set and a shaft locking assembly that releasably attaches the mold insert set to a mold plate of the injection molding system. Each mold insert of the mold insert set defines at least a portion of a mold cavity. The shaft locking assembly is displaceable between a locked position in which the mold insert set is held to the mold plate and an unlocked position in which the mold insert set is removable from the mold plate. | 2013-10-31 |
20130287880 | PRESS MOLDING APPARATUS - A press molding apparatus ( | 2013-10-31 |
20130287881 | IMPRINT MOLD FOR MANUFACTURING BIT-PATTERNED MEDIUM AND MANUFACTURING METHOD OF THE SAME - There is provided an imprint mold for manufacturing a bit-patterned medium with an imprint method, wherein dot-shaped protrusions are formed on a main surface of a substrate, so as to be a base of a magnetic material region in the bit-patterned medium, with the dot-shaped protrusions formed at a specific cycle in a specific direction on the main surface of the substrate, wherein the dot-shaped protrusions are formed by being surrounded by lattice-shaped grooves formed by shaving the main surface of the substrate and making a plurality of continuous planar view line-shaped grooves cross each other; and a width of each line-shaped groove is smaller than a width of each dot-shaped protrusion in the specific cycle. | 2013-10-31 |
20130287882 | APPARATUS FOR CASTING A NON-PNEUMATIC TIRE - This invention relates generally to an apparatus for casting a portion of a tire, and, more specifically, to an apparatus that has a cap and an outer ring that are rotatably attached to a fixed portion of the molding apparatus for centrifugally molding the spokes of a non-pneumatic tire from polyurethane or some other suitable material. The cap and outer ring have separate rotatable attachments to the apparatus and are not otherwise connected to each other, so they are free to rotate without obscuring the pouring slot of the mold. | 2013-10-31 |
20130287883 | Injection-Moulding Machine with a Shut-Off Needle - This relates to an injection-moulding machine comprising a hot runner for feeding a melt into a mould, a shut-off needle for closing or opening the hot runner, a piston connected to the shut-off needle, dividing the housing into first and second chambers, and a covering plate with a first and a second fluid | 2013-10-31 |
20130287884 | Mold-Tool System Including Body Having A Variable Heat Transfer Property - A mold-tool system ( | 2013-10-31 |
20130287885 | TWO-PLATEN HYBRID INJECTION MOLDING MACHINE - An injection molding machine comprises a machine base, and a stationary platen and a moving platen supported by the base. Each platen supports a respective stationary and moving mold half for forming a mold between the platens. An electrically driven platen actuator is coupled to the moving platen for advancing and retracting the moving platen between mold-closed and mold-open positions. At least one hydraulic clamp actuator is coupled to the platens for clamping together the stationary and moving platens when the moving platen is in the mold-closed position. A hydraulically powered rotary injection drive is coupled to the plasticizing screw for rotating the screw, and a hydraulic injection actuator is coupled to a plasticizing screw for injecting the injection material into the mold. | 2013-10-31 |
20130287886 | Injection-Moulding Machine - An injection-moulding machine comprising a hot runner, arranged in a manifold, for feeding a melt into a mould, a shut-off needle for optionally closing or opening the hot runner, a piston connected to the needle, is arranged in a housing with an opening and to which a fluid can be applied from both sides, and a covering plate having two fluid feeds, into the opening wherein the covering plate, the hot runner manifold and the housing are arranged in such a way that, at a first temperature of the manifold, a distance remains between the housing and the covering plate and, at a second higher temperature the thermal expansion of the manifold and/or housing causes the housing to come into contact with the covering plate, closing the opening. In a further embodiment, a flexible seal is provided between the housing and the covering plate. | 2013-10-31 |
20130287887 | Valve-Stem Assembly Removable from Runner System While Valve-Actuator Assembly Remains Connected with Manifold Assembly - A mold-tool system ( | 2013-10-31 |
20130287888 | Mold-Tool System having Manifold Extension and Biasing Assembly - A mold-tool system ( | 2013-10-31 |
20130287889 | NOZZLE-TIP APPARATUS INCLUDING A NOZZLE-TIP BODY HAVING PRESSURE-RELIEF FEATURE - A nozzle-tip apparatus ( | 2013-10-31 |
20130287890 | INHIBITOR OF THE PRODUCTION OF ADVANCED GLYCATION END PRODUCTS - The present invention provides an inhibitor of the production of an advanced glycation end product, which contains, as active ingredients, one or more sugar alcohols selected from maltitol and sorbitol. The present invention also provides a medicament for the prevention and/or treatment of lifestyle diseases, particularly diabetes or diabetic complications, which contains, as active ingredients, one or more sugar alcohols selected from maltitol and sorbitol. The medicament causes less adverse drug reactions. | 2013-10-31 |
20130287891 | DISPOSABLE COMBINED SQUEEZER/STIRRER/DISPENSER/BREWER DEVICE - A disposable packaging form is provided for brewed, hot drinks. The invention allows a user to brew the hot drink, squeeze out the brewed contents, and stir the contents of the hot drink. Each action can be performed multiple times before disposal. In some embodiments, the device of the present invention dispenses sweeteners, creamers, flavorings and condiments. The present invention frees the user of the inconvenience of having to collect, wash, or dispose of the stirrers, squeezers and bags of the hot drink individually. | 2013-10-31 |
20130287892 | MILK PROTEIN CONCENTRATES - A method for making a milk protein concentrate can comprise heating a liquid milk composition at near its natural pH to a temperature that causes the whey protein in the milk to bind to the casein in the milk to form protein aggregates. After cooling, the liquid milk composition can be subjected to membrane filtration using a membrane filter having a large pore size. The protein aggregates are retained to yield a milk protein concentrate. The concentrate can be further treated to provide a concentrate having a lowered lactose content. | 2013-10-31 |